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Reduced recanalization rates of the great
saphenous vein after endovenous laser treatment
with increased energy dosing: Definition of a
threshold for the endovenous fluence equivalent
Thomas Michael Proebstle, MD, MSc,a Thomas Moehler,b and Sylvia Herdemann, MD, a,b Heidelberg
and Mainz, Germany
Background: Recent reports indicated a correlation between the amount of energy released during endovenous laser
treatment (ELT) of the great saphenous vein (GSV) and the success and durability of the procedure. Our objective was
to analyze the influence of increased energy dosing on immediate occlusion and recanalization rates after ELT of the GSV.
Methods: GSVs were treated with either 15 or 30 W of laser power by using a 940-nm diode laser with continuous fiber
pullback and tumescent local anesthesia. Patients were followed up prospectively with duplex ultrasonography at day 1
and at 1, 3, 6, and 12 months.
Results: A total of 114 GSVs were treated with 15 W, and 149 GSVs were treated with 30 W. The average endovenous
fluence equivalents were 12.8  5.1 J/cm2 and 35.1  15.6 J/cm2, respectively. GSV occlusion rates according to the
method of Kaplan and Meier for the 15- and 30-W groups were 95.6% and 100%, respectively, at day 1, 90.4% and 100%
at 3 months, and 82.7% and 97.0% at 12 months after ELT (log-rank; P  .001). An endovenous fluence equivalent
exceeding 20 J/cm2 was associated with durable GSV occlusion after 12 months’ follow-up, thus suggesting a schedule
for dosing of laser energy with respect to the vein diameter.
Conclusions:Higher dosing of laser energy shows a 100% immediate success rate and a significantly reduced recanalization
rate during 12 months’ follow-up. (J Vasc Surg 2006;44:834-9.)During recent years, endoluminal treatment modalities
have evolved for the thermal ablation of the incompetent
great saphenous vein (GSV). Soon after the introduction of
a bipolar endovenous radiofrequency closure technique,1
endovenous laser treatment (ELT) of the GSV was pre-
sented, initially using diode lasers with 810- and 940-nm
wavelengths.2 From the very beginning, besides the discus-
sion of whether major tributaries at the saphenofemoral
junction can be left untreated, the immediate success rate of
endovenous occlusion of the GSV and its durability were in
the focus. Soon it became apparent that, particularly after
ELT, recanalization of initially occluded GSVs is a relevant
process that starts immediately thereafter.3,4 Multiple re-
gression analysis of a prospectively obtained set of clinical
data finally suggested that as soon as 3 months after laser
treatment, there might be a dose-response relationship
between laser energy and a persistent occlusion of the
GSV.5 As a consequence of these findings, we changed our
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834endovenous laser standard protocol from a 15-W continu-
ous pullback to a to a 30-W continuous pullback treatment
schedule. Reducing the pullback speed at the same time, we
were able to administer approximately a threefold amount
of laser energy per centimeter of vein length.
In this study, we prospectively followed up the recana-
lization events of the above-mentioned 15- and 30-W
treatment cohorts for 12 months after ELT to test the
hypothesis that an increase of the dose of laser energy
would result in improved immediate success and recanali-
zation rates.
PATIENTS AND METHODS
Patients. Patients with chronic venous insufficiency of
all clinical stages presented for routine evaluation in our
phlebology clinic. If the clinical stage was C2 or higher and
functional testing by duplex scanning showed an incompe-
tent GSV with reflux of more than 500 milliseconds after
the Valsalva maneuver or manual augmentation, patients
were selected for ELT in an outpatient setting. The first
patient cohort was treated with a 940-nm diode laser at
15 W of laser power. After we detected a dose-response
relationship between administered laser energy and treat-
ment success,5 our standard treatment was changed to 30
W of laser power for consecutive patients. There were no
specific exclusion criteria, apart from concomitant acute
disease preventing any surgical or interventional treatment
of varicose veins. Patients had to give written informed
consent in accordance with the Helsinki declaration. The
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Proebstle, Moehler, and Herdemann 835treated patients were representative of the patient popula-
tion referred to a university clinic (Table I).
Administration of laser energy. At the time of this
study, ELT was the only treatment. Additional treatment
measures such as sclerotherapy or miniphlebectomy were
scheduled 3 months after ELT, if necessary. In the first
cohort of patients (group A), 15 W of laser power of a
940-nm diode laser (Dornier MedTech Europe, Wessling,
Germany) was administered continuously while the laser
fiber was pulled back manually with a constant velocity of
approximately 5 mm/s. In the second cohort (group B),
laser treatment was administered with the same laser system
but with 30 W of laser power and a constant pullback
velocity of approximately 3 to 4 mm/s. The maximum vein
diameter at the saphenofemoral junction before treatment,
the length of the treated vein, and the total laser treatment
time were measured.
Otherwise, ELT was performed as previously de-
scribed.4 In brief, the GSV was punctured with duplex
guidance at the distal point of reflux with an 18-gauge
needle. With the help of a coated J-tip guidewire (0.035
inches), a 5F angiocatheter was placed with duplex guid-
ance close to the saphenofemoral junction. The guidewire
then was replaced by a 600-m laser fiber connected to a
940-nm diode laser. The desired position of the laser fiber
Table I. Patient characteristics and CEAP classification
of treated legs
Variable
Group
940 nm, 15 W 940 nm, 30 W
No. patients N  85 N  118
Female sex n  61 (73%) n  77 (65%)
Age, y, median (range) 61 (27-93) 55 (16-78)
BMI, kg/m2, median
(range) 25.3 (16.8–48.8) 25.4 (17.4-47.3)
GSV diameter, mm,
median (range)* 6.1 (2.0–17.3) 6.7 (2.8-16.1)
Treated vein length, cm,
median (range) 60 (18–90) 55 (15-90)
TLA (mL) per centimeter
vein length,
(mean  SD) 9.5  2.9 11.1  3.8
No. treated legs 114 (100%) 149 (100%)
C2 114 (100%) 149 (100%)
C3 60 (53%) 78 (52%)
C4 63 (55%) 38 (26%)
C5 2 (2%) 4 (3%)
C6 19 (17%) 6 (4%)
EP 109 (96%) 146 (98%)
ES 5 (4%) 3 (2%)
AS 114 (100%) 149 (100%)
AP 69 (61%) 51 (34%)
AD 5 (4%) 3 (2%)
PR 114 (100%) 149 (100%)
PO 0 (0%) 0 (0%)
BMI, body mass index; TLA, tumescent local anesthesia; GSV, great saphe-
nous vein.
Data are n (%) unless otherwise noted.
*Measured in the supine position.tip was again ascertained by duplex scanning. After posi-tioning of the fiber tip, tumescent local anesthesia was
infiltrated with duplex guidance and amotor pump into the
perivenous intrafascial space. One liter of tumescent local
anesthesia was prepared from 1 L of physiological saline
(0.9%), prilocaine 700mg, epinephrine 1mg, and 10mL of
bicarbonate 8.4%, as described previously.6 Without fur-
ther delay after infiltration, laser energy was administered as
described previously.
After complete removal of the fiber, an eccentric compres-
sion bandage was applied over the course of the treated vein
for 24 hours. Additionally, the patient had to wear graduated
compression stockings (30 mm Hg) continuously day and
night for 8 days. For the same period, patients had to admin-
ister low-molecular-weight heparin (2500 IU dalteparin sub-
cutaneously) once daily. No sedation was applied, and the
patients had towalk immediately after the procedure.Diclofe-
nac was prescribed (75 mg twice daily), and patients were
advised to use it for pain control as necessary.
Calculation of energy deposits. After each treat-
ment, the total amount of delivered laser energy was dis-
played in joules by the laser device. The quotient of total
laser energy in joules and the treated vein length in centi-
meters was then used to calculate the average linear en-
dovenous energy density (LEED). To take into account
different diameters of the GSV with respect to the admin-
istered laser energy, a cylindrical approximation of the inner
vein surface was used to calculate a fluencelike parameter.5
The diameter of the vein was measured with patients in the
supine position before the start of ELT on the basis of the
assumption that even after administration of tumescent
anesthesia, the inner vein surface is still there, even if it is
folded; therefore, the vein in its entirety appears with a
smaller diameter in ultrasound B-scan. The quotient of
released laser energy in joules and the approximated inner
vein surface we call the endovenous fluence equivalent
(EFE). To call it equivalent seems necessary because EFE
does not exactly resemble the definition of a fluence: unlike
in transcutaneous laser treatment, in which the laser beam
hits the targeted surface perpendicularly and in a homoge-
nous fashion, in ELT the laser beam geometry is inhomo-
geneous with respect to the targeted inner vein surface.
Follow-up examinations. Patients were re-examined
with duplex B-scan at day 1 after the procedure and 1, 3, 6,
and 12 months thereafter. The GSV was tested for recana-
lization by use of color duplex and compression sonogra-
phy elicited by the ultrasound probe. The distance from the
saphenofemoral junction to the beginning of the occluded
vein segment was measured, and if this distance exceeded
5 cm or if any part of the treated GSV showed flow signals
on augmentation or Valsalva maneuver, then the GSV was
judged recanalized. If recanalization did not affect the
entire length of the treated GSV, then the recanalization
was termed incomplete, either proximally or distally. At the
same time, duplex scanning was used to detect new patho-
logic refluxes, particularly within the tributaries originating
from the saphenofemoral junction or perforating veins in
the course of the treated GSV.
r ELT
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formed by using the StatXact 3.0 software package (Cytel
Software Corporation, Cambridge, Mass). LEEDs and EFEs
were compared by using the Wilcoxon/Mann-Whitney test.
The log-rank test was used to compare the 15- and 30-W
cohorts in Kaplan-Meier analysis. All tests were two sided.
RESULTS
In group A, with continuous use of a 940-nm laser at
15 W, ELT of the GSV was performed on 85 patients (114
limbs). In group B, 118 patients (149 limbs) were treated
with 30 W (Table I). The median treated vein length was
60 cm (range, 18-90 cm) in group A and 55 cm (range,
15 90 cm) in group B. The maximum diameters of the
GSV, age of patients, body mass index, and distribution of
sex were similar in the two groups (Table I). Clinical stages
before treatment according to the CEAP classification were
slightly asymmetric (Table I): legs of patients receiving
15-W treatment showed a higher rate of skin alterations
(C4) and venous ulcer disease (C5 and C6). The amount of
tumescent local anesthesia infiltrated along the GSV did not
differ significantly between the treatment groups (Table I).
Immediate success rates. At day 1 after ELT in the
30-W cohort, all GSVs were completely closed by duplex
ultrasound examination, thus resulting in an immediate
occlusion rate of 100% (Table II). In the 15-W cohort, 6
(5.2%) of 114 treated vessels remained open at day 1 after
treatment. However, 1 week after ELT, one of these ini-
tially open GSVs showed a complete occlusion, thus result-
ing in a total immediate closure rate of 95.6%. The differ-
ence in immediate occlusion rates between the two groups
was statistically significant (P  .029).
Recanalization of GSVs during follow-up. At 1, 3,
and 6 months after ELT in the 30-W group, no recanalized
GSV was observed. After 12 months, one complete recan-
Table II. Duplex follow-up of GSVs after ELT: limbs at r
Variable Day 1 1
15 W
Lost to follow-up 0
Limbs at risk 114 10
Occluded GSVs 108 10
Proximally recanalized 1*
Distally recanalized 0
Completely recanalized 5
Total recanalization events 6*
Kaplan-Meier estimate 95.6% 9
30 W
Lost to follow-up 0
Limbs at risk 149 14
Occluded GSVs 149 14
Proximally recanalized 0
Distally recanalized 0
Completely recanalized 0
Total recanalization events 0
Kaplan-Meier estimate 100% 10
GSV, Great saphenous vein; ELT, endovenous laser treatment.
*One initially unoccluded GSV closed completely within the first week aftealization and two incomplete recanalizations were observed(Table II). With 100 limbs at risk at that time, this repre-
sents an occlusion rate of 97% at 12 months. In the 15-W
group, partial and complete recanalizations occurred more
frequently during the follow-up period (recanalization at
3 months, 9.6%; occlusion rate at 12 months, 82.7%;
Table II). It is interesting to note that besides recanaliza-
tion events originating from the saphenofemoral junction,
recanalization originating from more distal parts of the
GSV was also observed. The number of occluded and
recanalized limbs of any recanalization patterns were ana-
Fig 1. Kaplan-Meier plot of recanalization events observed dur-
ing 12 months’ follow-up in great saphenous veins (GSVs) treated
with either 15 or 30 W of laser power according to data displayed
in Table II. The standard error of Kaplan-Meier estimates was less
than 0.05 at all times. ELT, Endovenous laser treatment.
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lost to follow-up (Fig 1). Log-rank testing of these data
revealed a significantly reduced recanalization frequency for
the 30-W treatment group (P  .0001).
Linear endovenous energy density. With ELT at 15
W, an average LEED of 23.6  4.9 J/cm of vein length
(mean SD) was delivered. The maximum LEED values
that were administered in recanalized GSVs were 28.2
and 30.0 J/cm for 6 and 12 months’ follow-up, respec-
tively (Table III). With ELT at 30 W and a reduced
pullback velocity, an average LEED of 69.9 18.7 J/cm
of vein was administered. Recanalization events were
seen only at 12 months’ follow-up when this energy level
was delivered, whereas earlier recanalizations were not
observed in this cohort. Additionally, the maximum
LEED administered to one subsequently recanalized
GSV was 100 J/cm, an outlier that could be related to a
treated vein length of only 15 cm. The other two events
were incomplete recanalizations, with LEEDs of 47 and
60 J/cm of vein length.
As displayed in Table III, LEED values of GSVs that
recanalized within the first 3 months after ELT (median,
18.4 J/cm) differed significant from LEED values of GSVs
that were still occluded after this time (median, 24.2
J/cm). Remarkably, LEED values of GSVs that recanalized
at 6 or 12 months after ELT did not show such a difference
when compared with values of GSVs that were still oc-
cluded after 12 months.
Endovenous fluence equivalent. Calculating the EFE
resulted in an average value of 12.8  5.1 J/cm2 (mean 
SD) for the 15-W cohort and an average of 35.1  15.6
J/cm2 for the 30-W group. Again, recanalizations that
happened within the first 3 months after ELT among GSVs
treated with 15 W were significantly linked to lower levels
of administered EFE (median, 7.4 J/cm2) compared with
EFE values of GSVs that were still closed after 3 months
Table III. Linear endovenous energy densities (LEED) an
recanalized GSVs
Variable
Recanalized
until 3 mo after
ELT
Occluded 3 mo
after ELT
15 W
No. events 11 103
LEED (J/cm) 18.4 (13.1-28.2) 24.2 (11.8–35.5)
EFE (J/cm2) 7.4 (5.0-11.0) 12.8 (2.8-37.3)
30 W
No. events 0 149
LEED (J/cm) — 68.4 (33.0-156.0)
EFE (J/cm2) — 32.2 (13.1–93.7)
GSV, Great saphenous vein; ELT, endovenous laser treatment.
P values are results of Wilcoxon/Mann-Whitney tests, recanalized vs occlud
†GSV recanalizations with 30 W:
One complete recanalization; total treated vein length was only 15 cm (100
One distal recanalization with pathologic reflux transferred by the V. acc. a
One distal recanalization originating from a medial thigh perforator (60 J/
*Only patients with completed 12-mo follow-up were included.(median, 12.8 J/cm2; Table III). In contrast, EFE values ofGSVs that recanalized between 3 and 12 months after the
intervention did not differ significantly from EFE values of
GSVs that were still occluded at 12 months, and this was
true for the 15- and 30-W treatment groups (Table III).
However, the amount of EFE administered during ELT
was inversely related to the subsequently observed recana-
lization rates during 12 months’ follow-up (Fig 2). Addi-
tionally, examining only those limbs with complete 12-
month follow-up demonstrated a clear inverse relationship
between EFE and recanalization rates (Table IV). Taking
together both groups over the period of 12 months—apart
from the single outlier at 67.8 J/cm2 with an extraordinar-
ily short treated vein length of only 15 cm—the maximum
EFE associated with recanalization during that period was
Fig 2. Recanalization rates observed during 12 months of
follow-up drawn against clustered endovenous fluence equivalents.
Open bars represent great saphenous veins (GSVs) treated with
15 W of laser power, hatched bars represent GSVs treated with
30W of laser power, and solid bars represent the cumulative results
of both groups.
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limbs in the 15-W group and from 145 limbs in the 30-W
group (Table V). In the latter group, 39 had been treated
with an EFE less than 25 J/cm2 and 106 with an EFE of 25
J/cm2 or greater. This discrimination was made at 25
J/cm2 to examine whether side effects would be less below
this limit, thus allowing the physician to treat the patients’
GSVs in a window between 20 and 25 J/cm2 and achieve
both reliable occlusion results and a favorable side-effect
profile. However, when the frequencies of the listed side
effects between each column in Table V were analyzed by
using the Fisher exact test, no statistically significant differ-
ence could be detected. The same was true when the
Wilcoxon/Mann-Whitney test was used to detect differ-
ences among duration intervals of various side effects, eg,
durations of paresthesia or posttreatment induration.
The most frequent side effects (in the order of 80%)
were ecchymoses and pain at the treatment site. Use of
analgesics and subcutaneous indurations were noted in
approximately 60% of treated limbs. Other side effects were
far less frequent; however, the duration of some side effects
reached 1 year in some patients. Among these long-duration
side effects were induration, paresthesia, and hyperpigmen-
tation. Hyperpigmentation, which was observed in 1% to
3% of treated limbs, also showed the longest median dura-
tion (6-9months). No severe side effects such as skin burns,
infections, deep vein thrombosis, or pulmonary embolism
Table IV. GSV recanalization rates during 12 months’ fo
administered endovenous fluence equivalent (EFE): only l
Treatment group x  10 10  x  15
15-W group recanalization rate 13 of 30 (43.3%) 5 of 43 (11.6
30-W group recanalization rate Not done 0 of 2 (0%)
Both groups; cumulative
recanalization rate 13 of 30 (43.3%) 5 of 45 (11.1
Table V. Side effects after 15- or 30-W laser treatment
Variable 15 W: all treatments
No. treated legs 107
Longitudinal endovenous energy density,
J/cm; median (range) 23.5 (11.8-35.5)
EFE, J/cm2, median (range) 12.2 (2.8-37.4)
Side effects, % affected limbs; median (maximum) duration (wk)
No side effects 7%
Ecchymosis 78%; 2 (8)
Pain 72%; 1 (4)
Analgesics 55%; 1 (4)
Induration along vein 62%; 4 (16)
Phlebitic reaction 11%; 1.5 (4)
Paresthesia 5%; 2 (4)
Hyperpigmentation 1%; 26 (26)
EFE, Endovenous fluence equivalents.have been observed.DISCUSSION
When ELT was introduced for ablation of saphenous
veins, little was known about the mechanisms of action and
frequency of recanalization events after such interventions.
Articles on a potential dose-response relationship between
energy dosing during ELT and the subsequent durability of
the vein occlusion were not published before 2004.5,7 We
performed a multiple regression analysis on procedural and
clinical parameters of ELT and determined EFE to be the
parameter that was the most significant predictor of subse-
quent recanalization events.5 Similarly, another study with
a total recanalization rate of approximately 20% during the
first 6 months after ELT did not observe such recanaliza-
tions if more than 80 J of laser energy had been adminis-
tered on each centimeter of treated GSV.7 Subsequently,
Timperman8 treated 100 patients with the intention to
exceed this level of 80 J/cm. However, in contrast to what
could have been expected, this subsequent study showed
five (5%) recanalization events during the first 6 months of
follow-up, even though at least 80 J/cm were administered
in all of these cases. Four additional cases were initial
treatment failures, thus leading to an unexpectedly low
total occlusion rate of 91% after 6 months.
In this study, we were able to demonstrate a striking
improvement in recanalization events during the first 12
months of follow-up when the energy dose was increased
up after endovenous laser treatment with respect to the
with complete 12-mo follow-up were included
E (J/cm2)
Total15  x  20 20  x  25 25  x
of 21 (4.8%) 0 of 5 (0%) 0 of 3 (0%) 19 of 102 (18.6%)
of 14 (14.3%) 0 of 15 (0%) 1 of 68 (1.5%) 3 of 100 (3.0%)
of 35 (8.6%) 0 of 20 (0%) 1 of 71 (1.4%) 22 of 201 (10.9%)
: all treatments 30 W: EFE 25 J/cm2 30 W: EFE 25 J/cm2
145 39 106
.4 (33-156) 53.1 (33-106) 72.2 (40.8-156)
.1 (13.1-93.7) 20.6 (13.1-24.9) 37.4 (25.0-93.7)
3% 3% 3%
80%; 2 (12) 82%; 2 (4) 79%; 2 (12)
%; 1.3 (12) 82%; 1.2 (3) 78%; 1.3 (12)
%; 0.3 (4) 59%; 1 (3) 65%; 0.3 (4)
63%; 4 (52) 56%; 4 (24) 65%; 4 (52)
12%; 1 (2) 5%; 1.3 (1.5) 14%; 1 (2)
12%; 4 (52) 13%; 2 (4) 11%; 4 (52)
3%; 39 (52) 3%; 26 (26) 3%; 39 (52)llow-
imbs
EF
%) 1
230 W
68
32
79
64with a laser power of 30 W. Whereas in the 15-W group,
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approximately 18% was observed during 12 months of
follow-up, this rate decreased to 3% in the 30-W group.
Furthermore, the three cases of recanalization in the latter
group were either incomplete (n 2) or a total recanaliza-
tion of a short GSV segment of only 15 cm of treatment
length. Finally, our rate of initial failures of GSV occlusion
decreased from 5 (4.4%) of 114 cases in the 15-W group to
0 in the 30-Wgroup. Additionally, apart from one outlier at
67.8 J/cm2, an EFE of more than 18.6 J/cm2 was not
associated with any recanalization events during 12months
of follow-up. Thus, it seems reasonable to suggest a thresh-
old of 20 J/cm2 for daily use in ELT of the GSV. This
simply transfers to an LEED of 6.3 J/cm for each millime-
ter of vein diameter (eg, the threshold LEED for a 6-mm-
diameter vein would be six times 6.3 J/cm, resulting in
approximately 38 J/cm, whereas a 10-mm diameter vein
should be treated with 63 J/cm).
Although it seems clear that sufficient dosing of laser
energy is the key for durable vein occlusions, the role of the
30-W laser power we used in this study is less defined.
Whether the same results could have been achieved by
delivering the same amounts of laser energy with a laser
power of 15W cannot be answered by this study. Addition-
ally, the reason for the differences between Timperman’s
results8 and the results of our present study is unknown. It
must be a matter of speculation why he still observed
failures of initial vein occlusion and additionally had a 5%
recanalization rate during the first 6 months after the
intervention despite using an EFE of 80 J/cm.
If we take a closer look at the technical differences
between Timperman’s and our treatment protocol, the
following points can be discussed. In both studies, a con-
tinuous pullback technique was engaged; however, because
Timperman used only 14 W of continuous laser power, he
had to use a much slower pullback velocity of approxi-
mately 6 cm of vein per second to exceed an energy dose of
80 J/cm. This slow velocity, together with a potentially
vein-perforating laser wavelength of 810 nm,9 could result
in axial cuts through the vein wall and lead to a paravasal
delivery of laser energy.We suggest that our 30-W protocol
with continuous fiber pullback might have at least two
advantages even if the laser wavelength of 940 nm also
could perforate the vein wall. First, 30 W of ELT generates
more vigorous steam bubble movements that can be easily
monitored by ultrasound B-scanmoving along the vein axis
over several centimeters. This behavior also enhances con-
vective heat transfer by enhancing the movements of laser-
heated intravenous blood. Second, a faster pullback speed
of approximately 3 cm/s might account for fewer axial vein
perforations. However, to prove these hypotheses and an-
swer these questions, comparative studies need to be con-
ducted prospectively. It is interesting to note that in this
study, the side effects (Table V) did not differ significantly
between laser schedules with different laser power and
different energy doses delivered during ELT.
This study proves a threshold value for energy dosing
but cannot answer the question about the definitive role of30 W of laser power. Another interesting hint concerning
the mechanisms of recanalization appears in Table III. The
significant dose-response relationship seems most pro-
nounced in conjunction with early recanalizations during
the first 3 months after ELT. When looking at LEED and
EFE values in conjunction with recanalization events at 6 or
12 months’ follow-up, it becomes apparent that these
LEED and EFE values are not significantly different for
recanalized and occluded GSVs. It could be speculated that
in these patients whose GSVs were found recanalized at 6
and 12 months, a neovascularization process was biologi-
cally more active than in patients with still-occluded GSVs.
An interestingmechanismof how inflammation of perivenous
tissue and arteriovenous fistulation could contribute to such
recanalization events was proposed recently.10
In conclusion, there is a pronounced dose-response
relationship between the administered EFE and durable
success of ELT of the GSV. A threshold value of 20 J/cm2
was proposed for the EFE, and this translates to a LEED of
6.3 J/cm for each millimeter diameter of the treated vein.
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